BCHE, Recombinant, Human (Butyrylcholinesterase, Cholinesterase, Acylcholine Acylhydrolase, Butyrylc

Butyrylcholinesterase (BCHE) is a major acetylcholine hydrolyzing enzyme in the circulation. Although it is present in significant amounts in human plasma, no endogenous physiological substrate has been described for this enzyme. It can degrade a large number of ester-containing compounds besides acylcholines, including neurotoxic organophosphate esters. Thus, it plays significant pharmacological and toxicological roles. It is thought to be involved in the pathological progression of Alzheimer's disease (AD) by depleting acetylcholine. In contrast to ACHE, it attenuates amyloid fibril formation in vitro. BCHE inhibitors have been used to delay symptoms of AD patients by virtue of their ability to enhance ACH availability. Its involvement in the cholinergic anti- inflammatory pathway connects BCHE and ACHE as possible markers of low-grade systemic inflammation observed in Type-2 diabetes, obesity, hypertension, coronary heart disease, and AD. BCHE can exist as monomers, dimers, or tetramers. Source: Chinese Hamster Ovary cell line, CHO-derived, Met1-Leu602, with a C-terminal 6-His tag. SDS-PAGE: 90-100kD, reducing conditions, Activity: Measured byits ability to cleave Butyrylthiocholine. The specific activity is >50,000 pmoles/min/ug, as measured under the described conditions. Endotoxin Level: <1EU/1ug (LAL) , Storage and Stability:, Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for at least 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.